Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR2 V564L |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 V564L | Advanced Solid Tumor | resistant | FGFR2 Inhibitor | Zoligratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980). | 25169980 |
FGFR2 V564L | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 V564L (PMID: 37270847). | 37270847 |
FGFR2 V564L | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | Pemigatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Pemazyre (pemigatinib) failed to inhibit Fgfr2 phosphorylation in cultured cells expressing FGFR2 V564L (PMID: 37270847). | 37270847 |
FGFR2 V564L | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Truseltiq (infigratinib) failed to inhibit Fgfr2 phosphorylation in cultured cells expressing FGFR2 V564L (PMID: 37270847). | 37270847 |
FGFR2 V564L | invasive ductal carcinoma | predicted - resistant | FGFR2 Inhibitor | Pemigatinib | Case Reports/Case Series | Actionable | In a clinical case study, FGFR2 V564L was identified at progression on Pemazyre (pemigatinib) treatment in a patient with metastatic ERBB2 (HER2)-negative invasive ductal carcinoma, who previously also harbored FGFR2-SHTN1 (reported as FGFR2-KIAA1598) (PMID: 37437229). | 37437229 |